Wegovy Pill Demonstrates Remarkable 16.6% Weight Loss in Pioneering Trial
Novo Nordisk, the Danish pharmaceutical titan, recently unveiled the revolutionary results of its oral Wegovy pill. The pill demonstrated that patients achieved an average weight loss of 16.6% following 64 weeks in the phase 3 Oasis 4 trial. This significant announcement led to a 5.4% jump in the company’s shares, as the company touts a “significant weight reduction” on par with its injectable version.
The trial involved patients suffering from obesity or overweight conditions, who were administered 25 milligrams of oral semaglutide daily. The findings revealed that the pill’s safety and tolerability profile mirrored that of the injectable version, with gastrointestinal issues such as nausea and vomiting being the most common side effects.
Chief Science Officer Martin Holst Lange compared the results with those of their competitors, stating, “What we’ve seen from our competitor is slightly more than 12% weight loss.” He was referring to Eli Lilly’s competing oral drug, orforglipron. The Wegovy pill is currently under FDA review, with a decision anticipated in Q4 2025. This could potentially provide millions of patients with a needle-free alternative to weekly injections.
[source]https://www.cnbc.com/2025/09/18/novo-nordisk-flags-wegovy-pill-weight-loss-in-line-with-injection.html[/source]